Evidence map›Paper›PMID 38140070›Full record

ReviewPharmaceutics2023

Advances in NIR-Responsive Natural Macromolecular Hydrogel Assembly Drugs for Cancer Treatment.

Chenyu Zhao, Boyue Pan, Tianlin Wang, Huazhe Yang, David Vance, Xiaojia Li, Haiyang Zhao, Xinru Hu, Tianchang Yang, Zihao Chen and 3 more

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Chenyu ZhaoChina Medical University-The Queen's University Belfast Joint College, China Medical University, Shenyang 110122, China.ORCID 0009-0007-9490-2062
Boyue PanChina Medical University-The Queen's University Belfast Joint College, China Medical University, Shenyang 110122, China.ORCID 0009-0001-3691-8206
Tianlin WangDepartment of Biophysics, School of Intelligent Medicine, China Medical University, Shenyang 110122, China.ORCID 0000-0002-6330-9721
Huazhe YangDepartment of Biophysics, School of Intelligent Medicine, China Medical University, Shenyang 110122, China.ORCID 0000-0003-3177-6517
David VanceChina Medical University-The Queen's University Belfast Joint College, China Medical University, Shenyang 110122, China.
Xiaojia LiTeaching Center for Basic Medical Experiment, China Medical University, Shenyang 110122, China.
Haiyang ZhaoTeaching Center for Basic Medical Experiment, China Medical University, Shenyang 110122, China.
Xinru HuThe 1st Clinical Department, China Medical University, Shenyang 110122, China.
Tianchang YangChina Medical University-The Queen's University Belfast Joint College, China Medical University, Shenyang 110122, China.
Zihao ChenChina Medical University-The Queen's University Belfast Joint College, China Medical University, Shenyang 110122, China.
Liang HaoDepartment of Chemistry, School of Forensic Medicine, China Medical University, Shenyang 110122, China.
Ting LiuChina Medical University-The Queen's University Belfast Joint College, China Medical University, Shenyang 110122, China.
Yang WangChina Medical University-The Queen's University Belfast Joint College, China Medical University, Shenyang 110122, China.ORCID 0000-0002-5276-7081
China Medical University · CNLiaoning University · CNQueen's University Belfast · GB

Funding

Innovation and Entrepreneurship Training Program for College Students of China Medical University 202210159011National Natural Science Foundation of China 82103693
6 · The paper itself

Abstract

Cancer is a serious disease with an abnormal proliferation of organ tissues; it is characterized by malignant infiltration and growth that affects human life. Traditional cancer therapies such as resection, radiotherapy and chemotherapy have a low cure rate and often cause irreversible damage to the body. In recent years, since the traditional treatment of cancer is still very far from perfect, researchers have begun to focus on non-invasive near-infrared (NIR)-responsive natural macromolecular hydrogel assembly drugs (NIR-NMHADs). Due to their unique biocompatibility and extremely high drug encapsulation, coupling with the spatiotemporal controllability of NIR, synergistic photothermal therapy (PTT), photothermal therapy (PDT), chemotherapy (CT) and immunotherapy (IT) has created excellent effects and good prospects for cancer treatment. In addition, some emerging bioengineering technologies can also improve the effectiveness of drug delivery systems. This review will discuss the properties of NIR light, the NIR-functional hydrogels commonly used in current research, the cancer therapy corresponding to the materials encapsulated in them and the bioengineering technology that can assist drug delivery systems. The review provides a constructive reference for the optimization of NIR-NMHAD experimental ideas and its application to human body.

Indexed as

cancer treatmentcontrolled releasehydrogel assembly drugsnatural macromolecularnear-infrared light

Identifiers

PMID38140070
PMCPMC10747500
OpenAlexW4389312582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.